Rilpivirin
Rilpivirin
Klass: A
Visa all info
Skriv ut
Kontakta oss
Produkter
EDURANT, Eviplera, Juluca, Odefsey, REKAMBYS
EDURANT, Eviplera, Juluca, Odefsey, REKAMBYSATC-koder
J05AG05, J05AR08, J05AR19, J05AR21
J05AG05, J05AR08, J05AR19, J05AR21Substanser
rilpivirin, rilpivirinhydroklorid
rilpivirin, rilpivirinhydrokloridSammanfattning
Inga skillnader mellan män och kvinnor i farmakokinetik eller effekt av rilpivirin har presenterats. Illamående har rapporterats oftare som biverkan hos kvinnor och mardrömmar oftare hos män.
Inga skillnader mellan män och kvinnor i farmakokinetik eller effekt av rilpivirin har presenterats. Illamående har rapporterats oftare som biverkan hos kvinnor och mardrömmar oftare hos män.Background
Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events. Visa hela bakgrundstexten
Pharmacokinetics and dosing
The manufacturer reports no clinically relevant differences between men and women in the pharmacokinetics of rilpivirine and suggests no differences in dosing [1].
Effects
Both men and women have been included in the randomized trials [1]. In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine, no difference between men and women was found in achieving virological suppression response [2].
Adverse effects
In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine or, zidovudine/lamivudine or abacavir/la......
Försäljning på recept
Visa hela försäljning på recept
Fler män än kvinnor hämtade ut läkemedel innehållande rilpivirin (ATC-kod J05AG05) på recept i Sverige år 2017, totalt 82 män och 31 kvinnor [3].
Referenser
Visa referenser
EDURANT (rilpivirine). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
- EDURANT (rilpivirine). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
- Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
Uppdaterat
Litteratursökningsdatum 7/18/2018
Litteratursökningsdatum 7/18/2018